0 222

Cited 18 times in

A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma.

DC FieldValueLanguage
dc.contributor.author금웅섭-
dc.contributor.author성진실-
dc.contributor.author최치환-
dc.date.accessioned2015-12-28T10:53:12Z-
dc.date.available2015-12-28T10:53:12Z-
dc.date.issued2014-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/138237-
dc.description.abstractPURPOSE: The purpose of this study was to investigate the efficacy and toxicity of radiation therapy (RT) following incomplete transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC). METHODS AND MATERIALS: The study was designed as a prospective phase 2 multicenter trial. Patients with unresectable HCC, who had viable tumor after TACE of no more than 3 courses, were eligible. Three-dimensional conformal RT (3D-CRT) was added for HCC treatment with incomplete uptake of iodized oil, and the interval from TACE to RT was 4 to 6 weeks. The primary endpoint of this study was the tumor response after RT following incomplete TACE in unresectable HCC. Secondary endpoints were patterns of failure, progression-free survival (PFS), time to tumor progression (TTP), overall survival (OS) rates at 2 years, and treatment-associated toxicity. Survival was calculated from the start of RT. RESULTS: Between August 2008 and December 2010, 31 patients were enrolled. RT was delivered at a median dose of 54 Gy (range, 46-59.4 Gy) at 1.8 to 2 Gy per fraction. A best objective in-field response rate was achieved in 83.9% of patients, with complete response (CR) in 22.6% of patients and partial response in 61.3% of patients within 12 weeks post-RT. A best objective overall response rate was achieved in 64.5% of patients with CR in 19.4% of patients and PR in 45.1% of patients. The 2-year in-field PFS, PFS, TTP, and OS rates were 45.2%, 29.0%, 36.6%, and 61.3%, respectively. The Barcelona Clinic liver cancer stage was a significant independent prognostic factor for PFS (P=.023). Classic radiation-induced liver disease was not observed. There were no treatment-related deaths or hepatic failure. CONCLUSIONS: Early 3D-CRT following incomplete TACE is a safe and practical treatment option for patients with unresectable HCC.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1051~1060-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHCarcinoma, Hepatocellular/drug therapy*-
dc.subject.MESHCarcinoma, Hepatocellular/mortality-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHCarcinoma, Hepatocellular/radiotherapy*-
dc.subject.MESHChemoembolization, Therapeutic/methods*-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDoxorubicin/administration & dosage-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIodized Oil/administration & dosage-
dc.subject.MESHLiver Neoplasms/drug therapy*-
dc.subject.MESHLiver Neoplasms/mortality-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLiver Neoplasms/radiotherapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProspective Studies-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRadiotherapy, Conformal/adverse effects-
dc.subject.MESHRadiotherapy, Conformal/methods*-
dc.subject.MESHSample Size-
dc.subject.MESHTreatment Failure-
dc.titleA prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorChihwan Choi-
dc.contributor.googleauthorWoong Sub Koom-
dc.contributor.googleauthorTae Hyun Kim-
dc.contributor.googleauthorSang Min Yoon-
dc.contributor.googleauthorJin Hee Kim-
dc.contributor.googleauthorHyung Sik Lee-
dc.contributor.googleauthorTaek Keun Nam-
dc.contributor.googleauthorJinsil Seong-
dc.identifier.doi10.1016/j.ijrobp.2014.08.011-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00273-
dc.contributor.localIdA01956-
dc.contributor.localIdA04203-
dc.relation.journalcodeJ01157-
dc.identifier.eissn1879-355X-
dc.identifier.pmid25303890-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0360301614036931-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameChoi, Chi Hwan-
dc.contributor.affiliatedAuthorKoom, Woong Sub-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorChoi, Chi Hwan-
dc.rights.accessRightsfree-
dc.citation.volume90-
dc.citation.number5-
dc.citation.startPage1051-
dc.citation.endPage1060-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.90(5) : 1051-1060, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.